Resmed gains FDA's nod for Smart Comfort, an AI-driven CPAP tool boosting sleep therapy personalization and adherence.
Resmed sees strong mask sales, strategic acquisitions and international expansion despite macro and competitive challenges.
IDEXX Laboratories' (IDXX) recent jump has investors questioning whether it's still the best bet—or if a stronger opportunity exists elsewhere. A closer look at its key competitor suggests there may be a clearer winner.
| Electronic Equipment, Instruments & Components Industry | Information Technology Sector | Michael J. Farrell BE, MBA, SM CEO | NYSE Exchange | 761152107 CUSIP |
| US Country | 9,980 Employees | 13 Nov 2025 Last Dividend | 31 Aug 2010 Last Split | 2 Jun 1995 IPO Date |
ResMed Inc. is a pioneering company focused on developing, manufacturing, distributing, and marketing medical devices alongside cloud-based software applications tailored for the healthcare markets. With its operational base divided between Sleep and Respiratory Care, and Software as a Service (SaaS), ResMed is at the forefront of offering innovative solutions for managing respiratory disorders. The company's extensive product lineup and software solutions cater to both medical and consumer needs, aiming to improve patient outcomes through advanced technology and connectivity. Founded in 1989 and headquartered in San Diego, California, ResMed markets its products globally through a combination of direct sales forces and a network of distributors, targeting sleep clinics, home healthcare dealers, and hospitals.